High thioredoxin-1 levels in rheumatoid arthritis patients diminish binding and signalling of the monoclonal antibody Tregalizumab

Abstract

The humanized non-depleting anti-CD4 monoclonal antibody Tregalizumab (BT-061) is able to selectively activate the suppressive function of regulatory T cells and has been investigated up to phase IIb in clinical trials in patients suffering from rheumatoid arthritis (RA). A pharmacokinetic-pharmacodynamic model based on clinical data from RA and healthy… (More)
DOI: 10.1038/cti.2016.69

Topics

Cite this paper

@inproceedings{Heim2016HighTL, title={High thioredoxin-1 levels in rheumatoid arthritis patients diminish binding and signalling of the monoclonal antibody Tregalizumab}, author={Katharina Heim and Benjamin D{\"a}lken and Stefanie Faust and Faiza Rharbaoui and Andr{\'e} Engling and H. Wallmeier and Theodor Dingermann and Heinfried H Radeke and J{\"{o}rg Sch{\"{u}ttrumpf and Marcus Gutscher}, booktitle={Clinical & translational immunology}, year={2016} }